The first adjuvant quadrivalent flu vaccine! The US FDA approves Fluad Quadrivalent for use in people ≥65 years of age to protect against seasonal flu!

February 26, 2020 / bioun / -- seqrus, a company of CSL group, an Australian biomedical giant, is a global leader in influenza prevention Recently, the company announced that the U.S Food and Drug Administration (FDA) has approved the first adjuvant quadruple influenza vaccine (flu vaccine, adjuvant), which is used to help the elderly aged 65 and above to resist seasonal influenza Anjana Narain, executive vice president and general manager of seqirus, said: "adults aged 65 and over are at high risk of influenza related complications every flu season, and it is very important to have available influenza vaccines to help protect this vulnerable population As part of our leading role in the first line of influenza prevention, we are pleased to provide healthcare providers and their patients with a quadruple influenza vaccine, flu quadrant, as another seasonal vaccine option against influenza " In the United States, influenza can have a serious impact on the elderly aged 65 and over, with higher rates of hospitalization and mortality in the elderly compared to healthy young adults During the 2017 / 18 influenza season, 70% of influenza related hospitalizations and 90% of influenza related deaths occurred in the 65 year old and older age group In this population, the effectiveness of influenza vaccine is often low, which is due to the age-related immune function decline, reducing the body's ability to produce adequate and protective immune response to the vaccine Fluad quantitative (aqiv) uses the same MF59 ® adjuvant technology as fluad (ativ, trivalent influenza vaccine) to generate a strong, broad and lasting immune response Compared with fluad (ativ), fluad quantitative (aqiv) has an additional influenza virus strain Fluad (ativ) is a very long-standing influenza vaccine Since it was first approved in 1997, more than 114 million doses have been distributed and distributed in 29 countries According to the Centers for Disease Control and Prevention (CDC), individuals aged ≥ 6 months should receive an influenza vaccine once a year, but this is particularly important for those aged 65 and over who are likely to suffer from serious complications of influenza Fluad quantitative (aqiv) and fluad (ativ) are the first and only batch of adjuvant seasonal influenza vaccines approved by the United States for adults aged 65 and above (BIOON Com) original source: seqirus Receives FDA approval for fluid? Quadrivalent (influenza vaccine, adjusted) for results 65 years and older